Business Description
Daewon Pharmaceutical Co Ltd
ISIN : KR7003220001
Compare
Compare
Traded in other countries / regions
003220.Korea IPO Date
1999-12-15Description
Daewon Pharmaceutical Co Ltd is active in the healthcare sector in Korea. Its main business involves antipyretics, respiratory drugs, cardiovascular drugs, and neuromuscular drugs. It also produces a range of health foods such as multivitamins. The company operates on a global basis.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.55 | |||||
| Debt-to-EBITDA | 3.04 | |||||
| Interest Coverage | 6.99 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.79 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.1 | |||||
| 3-Year EBITDA Growth Rate | 7.2 | |||||
| 3-Year EPS without NRI Growth Rate | 17.9 | |||||
| 3-Year FCF Growth Rate | 52.3 | |||||
| 3-Year Book Growth Rate | 7.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.92 | |||||
| 9-Day RSI | 53.62 | |||||
| 14-Day RSI | 53.07 | |||||
| 6-1 Month Momentum % | -10.04 | |||||
| 12-1 Month Momentum % | -0.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.15 | |||||
| Quick Ratio | 0.57 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 130.11 | |||||
| Days Sales Outstanding | 43.93 | |||||
| Days Payable | 28.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2 | |||||
| Dividend Payout Ratio | 0.23 | |||||
| 3-Year Dividend Growth Rate | 26.6 | |||||
| Forward Dividend Yield % | 2 | |||||
| 5-Year Yield-on-Cost % | 2.98 | |||||
| Shareholder Yield % | 0.86 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.82 | |||||
| Operating Margin % | 6.12 | |||||
| Net Margin % | 4.54 | |||||
| FCF Margin % | 5.91 | |||||
| ROE % | 9.22 | |||||
| ROA % | 5.08 | |||||
| ROIC % | 7.61 | |||||
| ROC (Joel Greenblatt) % | 11.98 | |||||
| ROCE % | 9.22 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.53 | |||||
| PE Ratio without NRI | 11.63 | |||||
| Shiller PE Ratio | 15.15 | |||||
| Price-to-Owner-Earnings | 14.42 | |||||
| PEG Ratio | 2.37 | |||||
| PS Ratio | 0.61 | |||||
| PB Ratio | 1.2 | |||||
| Price-to-Tangible-Book | 1.42 | |||||
| Price-to-Free-Cash-Flow | 10.36 | |||||
| Price-to-Operating-Cash-Flow | 6.24 | |||||
| EV-to-EBIT | 14.28 | |||||
| EV-to-EBITDA | 9.05 | |||||
| EV-to-Revenue | 0.82 | |||||
| EV-to-FCF | 13.96 | |||||
| Price-to-Projected-FCF | 1.01 | |||||
| Price-to-DCF (Earnings Based) | 0.89 | |||||
| Price-to-DCF (FCF Based) | 0.3 | |||||
| Price-to-Median-PS-Value | 0.5 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.81 | |||||
| Price-to-Graham-Number | 0.84 | |||||
| Earnings Yield (Greenblatt) % | 7 | |||||
| FCF Yield % | 9.77 | |||||
| Forward Rate of Return (Yacktman) % | 9.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Daewon Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 526,952.044 | ||
| EPS (TTM) (â‚©) | 1111 | ||
| Beta | 0.6 | ||
| Volatility % | 18.59 | ||
| 14-Day RSI | 53.07 | ||
| 14-Day ATR (â‚©) | 309.758574 | ||
| 20-Day SMA (â‚©) | 14969 | ||
| 12-1 Month Momentum % | -0.55 | ||
| 52-Week Range (â‚©) | 13530 - 19490 | ||
| Shares Outstanding (Mil) | 21.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Daewon Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Daewon Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Daewon Pharmaceutical Co Ltd Frequently Asked Questions
What is Daewon Pharmaceutical Co Ltd(XKRX:003220)'s stock price today?
The current price of XKRX:003220 is â‚©15030.00. The 52 week high of XKRX:003220 is â‚©19490.00 and 52 week low is â‚©13530.00.
When is next earnings date of Daewon Pharmaceutical Co Ltd(XKRX:003220)?
The next earnings date of Daewon Pharmaceutical Co Ltd(XKRX:003220) is .
Does Daewon Pharmaceutical Co Ltd(XKRX:003220) pay dividends? If so, how much?
The Dividend Yield %  of Daewon Pharmaceutical Co Ltd(XKRX:003220) is 2% (As of Today), Highest Dividend Payout Ratio of Daewon Pharmaceutical Co Ltd(XKRX:003220) was 0.47. The lowest was 0.16. And the median was 0.21. The  Forward Dividend Yield % of Daewon Pharmaceutical Co Ltd(XKRX:003220) is 2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers